Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Bolton

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
American Journal of Public Health|December 15, 2012
Interactions between HIV/AIDS and the environment: toward a syndemic frameworkAnna Talman, Susan Bolton, Judd L Walson
Journal of Public Health (Oxford, England)|August 23, 2013
Ventilated cookstoves associated with improvements in respiratory health-related quality of life in rural BoliviaDonee Alexander, Jacqueline Callihan Linnes, Susan Bolton, et al.
American Journal of Clinical Oncology|October 7, 2003
Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancerEmad Youssef, Samuel Tekyi-Mensah, Kimberly Hart, et al.
Cancer Metastasis Reviews|December 6, 2002
Fast neutron irradiation for prostate cancerJeffrey D Forman, Mark Yudelev, Susan Bolton, et al.
Clinical Prostate Cancer|March 30, 2004
Therapeutic postprostatectomy irradiationEmad Youssef, Jeffrey D Forman, Samuel Tekyi-Mensah, et al.
Urologic Oncology|February 19, 2004
Salvage radiation for a rising PSA following radical prostatectomyJordan Maier, Jeffrey Forman, Samuel Tekyi-Mensah, et al.
Anticancer Research|November 7, 2018
Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate CancerElisabeth I Heath, Lance K Heilbrun, Daryn Smith, et al.
Carcinogenesis|February 23, 2018
A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancerBatoul Farran, Gregory Dyson, Douglas Craig, et al.
American Journal of Cancer Research|November 13, 2018
The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancerGreg Dyson, Batoul Farran, Susan Bolton, et al.
The Oncologist|June 2, 2019
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate CancerElisabeth Heath, Lance Heilbrun, Heather Mannuel, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
American Journal of Public Health|December 15, 2012
Interactions between HIV/AIDS and the environment: toward a syndemic frameworkAnna Talman, Susan Bolton, Judd L Walson
Journal of Public Health (Oxford, England)|August 23, 2013
Ventilated cookstoves associated with improvements in respiratory health-related quality of life in rural BoliviaDonee Alexander, Jacqueline Callihan Linnes, Susan Bolton, et al.
American Journal of Clinical Oncology|October 7, 2003
Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancerEmad Youssef, Samuel Tekyi-Mensah, Kimberly Hart, et al.
Cancer Metastasis Reviews|December 6, 2002
Fast neutron irradiation for prostate cancerJeffrey D Forman, Mark Yudelev, Susan Bolton, et al.
Clinical Prostate Cancer|March 30, 2004
Therapeutic postprostatectomy irradiationEmad Youssef, Jeffrey D Forman, Samuel Tekyi-Mensah, et al.
Urologic Oncology|February 19, 2004
Salvage radiation for a rising PSA following radical prostatectomyJordan Maier, Jeffrey Forman, Samuel Tekyi-Mensah, et al.
Anticancer Research|November 7, 2018
Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate CancerElisabeth I Heath, Lance K Heilbrun, Daryn Smith, et al.
Carcinogenesis|February 23, 2018
A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancerBatoul Farran, Gregory Dyson, Douglas Craig, et al.
American Journal of Cancer Research|November 13, 2018
The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancerGreg Dyson, Batoul Farran, Susan Bolton, et al.
The Oncologist|June 2, 2019
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate CancerElisabeth Heath, Lance Heilbrun, Heather Mannuel, et al.
Pageof 1